1. Generics Bulletin

WIPO Patent Database Is Flawed And Promotes Linkage

 
• By Dave Wallace

An online register of global patent information for medicines launched by the WIPO and brand industry body IFPMA serves as a tool for patent linkage, contains no mechanisms to ensure accuracy, and is inappropriate for a UN agency to endorse, according to the IGBA.

Padlock
Pat-INFORMED Is A Patent Linkage Tool That Blocks Access, The IGBA Says • Source: Shutterstock

In an open letter to Francis Gurry, director general of the World Intellectual Property Organization (WIPO), the International Generic and Biosimilar medicines Association (IGBA) has sharply criticized an online register of global patent information launched by the WIPO and global brand body the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) last year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

Glenmark’s UK Dapagliflozin Blocked On Appeal After Teva Readied Launch

 
• By Dean Rudge

Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.

Sandoz Admits To Widescale Infringement In Resolving US Rinvoq Patent Tussle

 
• By Dean Rudge

Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.

More from Generics Bulletin